Ami Mehra, MD
Allergy & Immunology · Chelmsford, MANPI 1760400634
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $55,550 of the $63,603 with a category attached, or 87.3%. AstraZeneca accounts for 92.2% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $28,576 and has fallen 94.5% since, to $1,586 in 2025. Among allergy & immunology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 342 payments — averaging $185.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$59K
- Amgen$2K
- Pfizer$557
- Biocryst US Sales Co., LLC$369
- GSK$352
- Regeneron Healthcare Solutions, Inc.$290
- plus $2K from 17 others
What the payments were for
- Speaking & faculty fees$55,55087%
- Travel & lodging$1,1182%
- Food & beverage$6,78411%
- Education$1510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 165 | $58,613 |
| Amgen | 17 | $1,776 |
| Pfizer | 41 | $557 |
| Biocryst US Sales Co., LLC | 14 | $369 |
| GSK | 18 | $352 |
| Regeneron Healthcare Solutions, Inc. | 12 | $290 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $290 |
| CSL Behring | 11 | $241 |
| AbbVie | 6 | $200 |
| Novartis | 12 | $189 |
| Grifols USA, LLC | 5 | $137 |
| Pharming Healthcare, Inc. | 5 | $116 |
| Sanofi | 4 | $104 |
| Lilly USA, LLC | 3 | $77 |
| Kaleo, Inc. | 3 | $68 |
| Shire North American Group Inc | 3 | $53 |
| Ionis Pharmaceuticals, Inc. | 2 | $45 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $35 |
| GC Biopharma USA, Inc. | 1 | $30 |
| Cycle Pharmaceuticals Inc | 1 | $20 |
| Galderma Laboratories, L.p. | 1 | $17 |
| Alk-abello, Inc | 1 | $16 |
| Organon | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$63,603 in reported general payments places this provider in the 90th percentile of 114 allergy & immunology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrladeyoBerotralstat Hydrochloride | 14 | $576,517 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 36 | $99,368 |
| Breo ElliptaFluticasone/Vilanterol | 81 | $53,137 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $47,603 |
| TezspireTezepelumab-Ekko | 11 | $44,026 |
| XolairOmalizumab | 15 | $37,608 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $13,678 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $12,586 |
| Arnuity ElliptaFluticasone Furoate | 23 | $8,595 |
| Wixela InhubFluticasone Propion/Salmeterol | 41 | $8,104 |
| DuleraMometasone/Formoterol | 13 | $6,713 |
| Epinephrine | 23 | $3,596 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $2,003 |
| Montelukast Sodium | 95 | $1,507 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 44 | $1,188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biocryst US Sales Co., LLCOrladeyo | $369 | $576,51714 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $352 | $109,335164 claims |
| Grifols USA, LLCGamunex-C | $137 | $99,36836 claims |
| AstraZenecaTezspire, Breztri Aerosphere | $58,613 | $56,61224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 114 allergy & immunology providers in Massachusetts.
Other allergy & immunology in Chelmsford
- Angela AhujaChelmsford$14K
- Elizabeth YakaboskiChelmsford$2K
- Wanda PhipatanakulBoston$679K
- Jonathan BayukNorthampton$420K
- Kathleen BuchheitBoston$224K
- Francisco BonillaLeominster$188K
- Aleena BanerjiBoston$133K
- Margo StevensonSturbridge$98K
- Jeffrey GelfandBoston$84K
- Paul MaglioneBoston$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.